Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.

  title={Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.},
  author={Matjaz Sever and Kate J. Newberry and Srdan Verstovsek},
  journal={Leukemia & lymphoma},
  volume={55 12},
Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications. However, approximately 20-25% of patients develop resistance or intolerance to HU and must be treated with second-line therapies. Resistance is associated with disease transformation and reduced survival. However, given the dearth of large-scale controlled clinical trials in this patient population, there is no clear… CONTINUE READING


Publications referenced by this paper.
Showing 1-10 of 54 references

and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

JC Hernandez-Boluda, A Alvarez-Larran, M Gomez
Blood • 2012
View 4 Excerpts
Highly Influenced

Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia

F Cervantes, F Passamonti, G Barosi
Br J Haematol • 2011
View 4 Excerpts
Highly Influenced


H Gisslinger, R Kralovics, B Gisslinger

A phase II study of [ 46 ] givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy

Å Derolf, M Hultcrantz
Br J Haematol • 2013

Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research • 2013

Clinical [ 13 ] evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide

G Barosi, R Mesa, G Finazzi
Ann Hematol • 2013